Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Compass Therapeutics
Exelixis
ViroMissile, Inc.
Seattle Children's Hospital
St. Jude Children's Research Hospital
Jonsson Comprehensive Cancer Center
MacroGenics
City of Hope Medical Center
SAPU NANO (US) LLC
NeoTX Therapeutics Ltd.
AccSalus Biosciences, Inc.
West China Hospital
Coherus Oncology, Inc.
St. Jude Children's Research Hospital
Baylor College of Medicine
HiFiBiO Therapeutics
Pfizer
Exelixis
Jonsson Comprehensive Cancer Center
University of Virginia
Incyte Corporation
Incyte Corporation
Bristol-Myers Squibb
LaunXP Biomedical Co., Ltd.
Incyte Corporation
Sotio Biotech Inc.
Carisma Therapeutics Inc
Molecular Templates, Inc.
Xencor, Inc.
Pliant Therapeutics, Inc.
National Cancer Institute (NCI)
University of Florida
Lebanese University
Fate Therapeutics
Children's National Research Institute
Tempest Therapeutics
Fate Therapeutics
Xencor, Inc.
Xencor, Inc.
Pfizer
Incyte Corporation
Incyte Corporation
Abramson Cancer Center at Penn Medicine
Alliance for Clinical Trials in Oncology
Sichuan Huiyang Life Science and Technology Corporation
Taizhou EOC Pharma Co., Ltd.
Masonic Cancer Center, University of Minnesota
National Institutes of Health Clinical Center (CC)
Mirna Therapeutics, Inc.